GRAIL
(GRAL)
undefined
undefined%
At close: undefined
19.01
-1.91%
After-hours Jan 03, 2025, 05:22 PM EST
Company Description
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.
The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
It is also developing minimal residual disease and other post-diagnostic tests.
The company was incorporated in 2015 and is based in Menlo Park, California.
GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAIL
| Country | United States |
| IPO Date | Jun 12, 2024 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,360 |
| CEO | Robert P. Ragusa |
Contact Details
Address: 1525 O’Brien Drive Menlo Park, California United States | |
| Website | https://grail.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US3847471014 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Robert P. Ragusa | Chief Executive Officer & Director |
| Aaron Freidin | Chief Financial Officer |
| Abram Barth J.D., M.P.H. | General Counsel |
| Alice A. Chen | Vice President of Product & Head of Program Management Organization |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President |
| Dr. Satnam Alag Ph.D. | Senior Vice President of Software Engineering & Chief Security Officer |
| Nathan Hunkapiller Ph.D. | Senior Vice President of Research & Development |
| Paul Ciccolella | Senior Vice President of Research, Development & Operations |
| Rodger Currie | Vice President and Head of Government Affairs & Alliance Development |
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | President Biopharma Business & Europe |